Browse

Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study

DC Field Value Language
dc.contributor.authorEun, Hee Chul-
dc.contributor.authorKwon, Oh Sang-
dc.contributor.authorYeon, Je Ho-
dc.contributor.authorShin, Hyo Seung-
dc.contributor.authorRo, Byung In-
dc.contributor.authorSim, Woo Young-
dc.contributor.authorLee, Won-Soo-
dc.contributor.authorHong, Seung Phil-
dc.contributor.authorJi, Jae Hong-
dc.contributor.authorPark, Hwa Young-
dc.contributor.authorLew, Bark Lynn-
dc.contributor.authorCho, Han Kyong-
dc.contributor.authorKim, Byung Yoon-
dc.date.accessioned2012-07-03T08:49:08Z-
dc.date.available2012-07-03T08:49:08Z-
dc.date.issued2010-08-
dc.identifier.citationJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY; Vol.63(2); 252-258ko_KR
dc.identifier.issn0190-9622-
dc.identifier.urihttps://hdl.handle.net/10371/78325-
dc.description.abstractBackground: Dutasteride (Avodart) is a dual inhibitor of both type I and type II 5 alpha reductases, and thus inhibits conversion of testosterone to dihydrotestosterone, a key mediator of male pattern hair loss. Objectives: The aim of this randomized double-blind phase III study was to compare the efficacy, safety, and tolerability of dutasteride (0.5 mg) and placebo for 6 months of treatment in male patients with male pattern hair loss. Methods: A total of 153 men, 18 to 49 years old, were randomized to receive 0.5 mg of dutasteride or placebo daily for 6 months. Efficacy was evaluated by the change of hair counts, subject assessment, and photographic assessment by investigators and panels. Results: Mean change of hair counts from baseline to 6 months after treatment start was an increase of 12.2/cm(2) in dutasteride group and 4.7/cm(2) in placebo group and this difference was statistically significant (P = .0319). Dutasteride showed significantly higher efficacy than placebo group by subject self-assessment and by investigator and panel photographic assessment. There was no major difference in adverse events between two groups. Limitations: The study was limited to 6 months. Conclusions: This study clearly showed that 0.5 mg of dutasteride improved hair growth and was relatively well tolerated for the treatment of male pattern hair loss.ko_KR
dc.language.isoenko_KR
dc.publisherMOSBY-ELSEVIERko_KR
dc.subjectandrogenetic alopeciako_KR
dc.subjectdutasterideko_KR
dc.subjecttreatmentko_KR
dc.subjectmale pattern hair lossko_KR
dc.titleEfficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III studyko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor은희철-
dc.contributor.AlternativeAuthor권오상-
dc.contributor.AlternativeAuthor연제호-
dc.contributor.AlternativeAuthor신효승-
dc.contributor.AlternativeAuthor김병윤-
dc.contributor.AlternativeAuthor노병인-
dc.contributor.AlternativeAuthor조한경-
dc.contributor.AlternativeAuthor심우영-
dc.contributor.AlternativeAuthor류박린-
dc.contributor.AlternativeAuthor이원수-
dc.contributor.AlternativeAuthor박화영-
dc.contributor.AlternativeAuthor홍승필-
dc.contributor.AlternativeAuthor지재홍-
dc.identifier.doi10.1016/j.jaad.2009.09.018-
dc.citation.journaltitleJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY-
dc.description.citedreferenceSTOUGH D, 2007, J COSMET DERMATOL, V6, P9-
dc.description.citedreferenceOlsen EA, 2006, J AM ACAD DERMATOL, V55, P1014, DOI 10.1016/j.jaad.2006.05.007-
dc.description.citedreferenceOlsen EA, 2005, J AM ACAD DERMATOL, V52, P301, DOI 10.1016/j.jaad.2004.04.008-
dc.description.citedreferenceOLSZEWSKA M, 2005, J DRUGS DERMATOL, V4, P637-
dc.description.citedreferenceDebruyne F, 2004, EUR UROL, V46, P488, DOI 10.1016/j.eururo.2004.05.008-
dc.description.citedreferenceClark RV, 2004, J CLIN ENDOCR METAB, V89, P2179, DOI 10.1210/jc.2003-030330-
dc.description.citedreferenceRoehrborn CG, 2004, UROLOGY, V63, P709, DOI 10.1016/j.urology.2004.01.001-
dc.description.citedreferencePrice VH, 1999, NEW ENGL J MED, V341, P964-
dc.description.citedreferenceKaufman KD, 1998, J AM ACAD DERMATOL, V39, P578-
dc.description.citedreferenceBramson HN, 1997, J PHARMACOL EXP THER, V282, P1496-
dc.description.citedreferenceCanfield D, 1996, DERMATOL CLIN, V14, P713-
dc.description.citedreferenceCourtois M, 1996, BRIT J DERMATOL, V134, P47-
dc.description.citedreferenceDALLOB AL, 1994, J CLIN ENDOCR METAB, V79, P703-
dc.description.citedreferenceRUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25-
dc.description.citedreferenceOLSEN EA, 1994, DISORDERS HAIR GROWT, P257-
dc.description.citedreferenceTHIGPEN AE, 1993, J CLIN INVEST, V92, P903-
dc.description.citedreferenceCASH TF, 1992, J AM ACAD DERMATOL, V26, P926-
dc.description.citedreferenceJENKINS EP, 1992, J CLIN INVEST, V89, P293-
dc.description.citedreferenceRANDALL VA, 1991, BRIT J DERMATOL, V124, P146-
dc.description.citedreferenceNORWOOD OT, 1975, SOUTHERN MED J, V68, P1359-
dc.description.citedreferenceIMPERATO.J, 1974, SCIENCE, V186, P1213-
dc.description.citedreferenceHAMILTON JB, 1951, ANN NY ACAD SCI, V53, P708-
dc.description.tc2-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dermatology (피부과학전공)Journal Papers (저널논문_피부과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse